D.B.M. starts marketing pre-filled syringes containing Trisodium Citrate at different concentrations, C-LOCK 4% and C-LOCK 46.7%, within the European Union.
These syringes are a good alternative to heparin in maintaining catheter patency in patients.
Trisodium Citrate avoids the risks associated with systemic heparinization and is safe for use in patients with suspected or confirmed Heparin-Induced Thrombocytopenia.
Several clinical trials demonstrated the effectiveness of Trisodium Citrate as anticoagulant solution in maintaining catheter patency.